透過您的圖書館登入
IP:18.222.119.148
  • 期刊

台灣上市生技公司之績效評估-應用Hicks-Moorsteen生產力指數

摘要


本文以台灣2014至2019年生技產業26家上市廠商為對象,傳統麥氏生產力指數顯示平均值分別為1.009。代表在估計期間有0.89%的生產面生產力上升。西藥產業有2.55%的生產面生產力改善;醫療耗材產業有-1.38%的生產面生產力下降。因ΔT估計值均小於1,表示台灣上市生技公司的生產技術有待改善。Hicks-Moorsteen生產力指數指出生技產業、西藥產業、醫療耗材產業生產力均呈現生產面生產力下降。其原因為ΔROSE及ΔRME估計值均小於1。本文實證指出提高生產技術有助於台灣生技與製藥廠商的生產力。

並列摘要


This research focuses on 26 listed companies in Taiwan's biotechnology industry from 2014 to 2019. The traditional Malmquist Productivity Index shows that the average values are 1.009, which represents a 0.89% increase in production surface productivity during the estimation period. The western medicine industry has a 2.55% improvement in the production surface productivity; the medical consumable industry has a -1.38% reduction in the production surface productivity. Because the estimated values of ΔT are all less than 1, it indicates that the production technology of Taiwan-listed biotech companies needs to be improved. The Hicks- Moorsteen Productivity Index pointed out that the productivity of the biotechnology industry, the western medicine industry, and the medical consumables industry all showed a decline in production surface productivity. The reason is that the estimated values of ΔROSE and ΔRME are both less than 1. This research points out that improving production technology will help Taiwan's biotech and pharmaceutical manufacturers to produce productivity.

延伸閱讀